关键字不能为空!

Enter

Home » Patient Care » Departments & Services » Clinical Departments » Cardiology, Heart Center

Sun Ningling, Doctoral supervisor

DEPARTMENT OF Cardiology, Heart Center

Sun Ningling, Doctoral supervisor
  • Department:Cardiology, Heart Center
  • Gender:female
  • Title:Chief physician, Vice-director of Heart Center
Professional Highlights

    She is the chairman of Chinese Medical Association Hypertension Professional Committee, China Medicine Education Association Hypertension Professional Committee, China International Exchange and Promotive Association for Medical and Health Care Hypertension Professional Committee, Peking Medical Association Hypertension Professional Committee. She is the vice-chairman of China Hypertension League, Chinese Medical Association Women Doctor Society Cardiovascular Institute, the commission of National Pharmacopeia Committee, and the member of directors of China Medical Association Beijing Cardiovascular Institute, the vice-president of Beijing Hypertension Prevention & Management Society, et al. She is the member of ISH and AHA, the fellow of ESC.

    She is also the vice-chief editor of Chinese Journal of Geriatric Cardiovascular and Cerebrovascular Diseases, the vice-chief editors of Chinese Journal of Hypertension, the member of editorial committee of several medical magazines, including Chinese Journal of Cardiovascular Diseases, Chinese Journal of Clinical Pharmacology, Chinese Circulation Journal, and so on. At the same time, she is the special copy editor of Circulation Chinese Edition, AHA journals、European Heart Journal Excerpts Chinese Edition, AHA Journals Best Selection Chinese Reprint, et al.

Interests

Hypertension and related cardiovascular disease.

Research & Publications

[1] Sun N, Xi Y, Zhu Z, Yin H, Tao Q, Wang H, Wang L, Ma Z, Chen Y, Yao D. Effects of Anxiety and Depression on Arterial Elasticity of Subjects With Suboptimal Physical Health. Clin Cardiol, 2015, 38(10):614-20.
[2] Sun NL, Huo Y, Wang JG, Li NF, Tao J, Li Y, Yan XW, Jiang XJ, Li XW. Consensus of Chinese Specialists on Diagnosis and Treatment of Resistant Hypertension. Chin Med J (Engl), 2015, 128(15):2102-8.
[3] Ningling Sun, Yang Xi, Weizhong Han, Lichao Zhao, Hongyi Wang, and Yuanyuan Chen. Relationship of 24-h urinary sodium excretion with blood pressure, arterial distensibility, and urine albumin in Chinese hypertensive patients. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2015, 7(S): F37-43.
[4] Han W, Sun N, Chen Y, Wang H, Xi Y, Ma Z. Validation of the Spot Urine in Evaluating 24-Hour Sodium Excretion in Chinese Hypertension Patients.Am J Hypertens. 2015, 28(11):1368-75.
[5] Sun N, Wang H, Sun Y, Chen X, Wang H, Zhao L, Wang J, Zhu Z. Detecting diabetic risk using the oral glucose tolerance test in Chinese patients with hypertension: a cross-sectional study. Hypertens Res. 2014, 37(1): 82-87.
[6] Dan Yao, Ning-Ling Sun. Hyperhomocysteinemia Accelerates Collagen Accumulation in the Adventitia of Balloon-Injured Rat Carotid Arteries via Angiotensin II Type 1 Receptor. Int. J. Mol. Sci. 2014, 15, 19487-19498.
[7] Sun NL, Wang LY, Xi Y, Hu QZ. Effect of renin-angiotensin system on arterial function in persons with acute mountain sickness. Int J Cardiol. 2013, 167(4):1641-2.
[8] Zhu JR, Sun NL, Yang K, Hu J, Xu G, Hong H, Wang R, Tu YM, Ritter S, Keefe D; trial investigators. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension. Hypertens Res, 2012, 35(1): 28-33.
[9] Huang J, Sun NL, Hao YM, Zhu JR, Tu Y, Curt V, Zhang Y; Trial Investigators.Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy. Clin Exp Hypertens, 2011, 33(3):179-186.
[10] Zheng M, Zeng Q, Shi XQ, Zhao J, Tang CS, Sun NL, Geng B. Erythrocytic or serum hydrogen sulfide association with hypertension development in untreated essential hypertension. Chin Med J (Engl), 2011, 124(22):3693-3701.
[11] Song HF, Chen JF, Sun NL, Li HW. Effects of angiotensin II receptor antagonist olmesartan on renal hemodynamic variables and vascular structural properties in streptozotocin-induced diabetic rats. Chin Med J (Engl), 2011, 124(4):562-567.
[12] Guo X, Zhou C, Sun N. The neuropeptide catestatin promotes vascular smooth muscle cell proliferation through the Ca2+-calcineurin-NFAT signaling pathway. Biochem Biophys Res Commun, 2011, 407(4):807-812.
[13] Zhuang XF, Yin CQ, Wang HY, Sun NL. Distinctive effects of carvedilol in the non-infarct zone: remodeling of the ligated rat heart linked to oxidative stress. The journal of international medical research, 2009, 37(5):1354-1364.
[14] Zhuang XF, Zhao MM, Weng CL, Sun NL. Adipocytokines: A bridge connecting obesity and insulin resistance. Medical Hypotheses, 2009, 73(6):981-985.
[15] Xiao PANG, Ning-ling SUN. Calcineurin-NFAT signaling is involved in phenylephrine- induced vascular smooth muscle cell proliferation. Acta Pharmacologica Sinica, 2009, 30(5): 537-544. 
[16] Liu J, Sun NL, Yang J, Huang JH. Effects of losartan on fibrinolytic parameters and von Willebrand factor in Chinese subjects with hypertension: a comparative study versus atenolol. J Int Med Res, 2009, 37(3):595-600.
[17] Pang X, Sun NL. Calcineurin-NFAT signaling is involved in phenylephrine-induced vascular smooth muscle cell proliferation. Acta Pharmacol Sin, 2009, 30(5):537-544.
[18] Sun N, Xi Y, Jing S, Lu X. Morning blood pressure surge varies with age and gender in hypertensive individuals. Int J Cardiol, 2009,135(2):272-273.
[19] Ning-L. Sun, Jun-R. Zhu, Yanxing Zhao and Ying-M. Tu on Behalf of the Co-Diovan Trial Investigators. Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension. Current Medical Research and Opinion, 2008, 24(10): 2863–2871.
[20] Hui LI, Ning-ling SUN, Jin WANG, Ai-jun LIU, Ding-feng SU. Circadian expression of clock genes and angiotensin II type 1 receptors in suprachiasmatic nuclei of sinoaortic-denervated rats. Acta Pharmacol Sin, 2007, 28 (4):484-492.

Others

    Under her leadership, many related scientific researches and clinical pharmacological works have been accomplished, including National 12·5,National 10·5 Program, Spark Program, Fund of Ministry of Public Health, et al. Furthermore, the other two National Projects, National S&T Support Program(11·5) and National High-tech R&D Program(863) have been taken charge and carried out.
    She is the director or major international partner of many clinical pharmacological trials in hypertensive and high risk patients, including VALUE, ONTARGER/TRANSEND, OCEAN, AMISH, CRESENDO, RELY, RELY-able, INSPIRE ME, ALTITUDE, HPS2, et al.